Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 3/20 | 0.42 |
| ▸ | REN | P00797 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4408873 | 0.88 | CYP2D6 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL28413858 | 0.86 | CYP2D6 (0.44) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL19227630 | 0.86 | CA1 (0.58) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL56754 | 0.85 | CTSS (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL56753 | 0.85 | CTSS (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL4934738 | 0.85 | CTSS (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL18428106 | 0.85 | CYP2D6 (0.55) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL24387604 | 0.84 | CA1 (0.49) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL16285802 | 0.83 | CYP2D6 (0.46) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL272147 | 0.83 | CYP2D6 (0.46) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. | 2023-12-21 | — | — | US | disclosed |
| EP-4237086-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022093856-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022093856-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406860-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | CA1 3451/4885CA2 2768/4885CA7 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.